Your Health, We Care
Coadministration of brigatinib with a strong or moderate CYP3A inhibitor increased brigatinib plasma concentrations, which may increase the incidence of adverse reactions [see Clinical Pharmacology (12.3)]. Avoid coadministration of brigatinib with strong or moderate CYP3A inhibitors. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, modify dose as recommended.
Coadministration of brigatinib with a strong or moderate CYP3A inducer decreased brigatinib plasma concentrations, which may decrease the efficacy of brigatinib. Avoid coadministration of brigatinib with strong or moderate CYP3A inducers. If coadministration of moderate CYP3A inducers cannot be avoided, modify dose as recommended.
from FDA，2022.02
